SCHEMBL20122897

SCHEMBL20122897

Cc1nccc2c1[nH]c1c(-c3cccc(N4CCOCC4)c3)cc(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.43
STK4 Q13043 2/20 0.41
STK3 Q13188 2/20 0.41
LRRK2 Q5S007 2/20 0.41
JMJD6 Q6NYC1 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
ATR Q13535 2/20 0.40
ATRIP Q8WXE1 2/20 0.40
MAOA P21397 1/20 0.40
TBK1 Q9UHD2 4/20 0.40
MAPK8 P45983 1/20 0.40
MAPK10 P53779 1/20 0.40
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
RPS6KA3 P51812 1/20 0.39
PIK3R2 O00459 1/20 0.39
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664218 1.00 CAMK2D (0.43) CAMK2DSTK4STK3LRRK2JMJD6
SCHEMBL20122840 0.84 PDE4B (0.45) LRRK2MAOATBK1MAPK8
SCHEMBL30664196 0.84 PDE4B (0.45) LRRK2MAOATBK1MAPK8
SCHEMBL30664175 0.82 CNR2 (0.54) ATRATRIPPSEN1PSEN2APH1B
SCHEMBL20122865 0.82 CNR2 (0.54) ATRATRIPPSEN1PSEN2APH1B
SCHEMBL20122930 0.81 MAOA (0.61) MAPKAPK2MAOAMAPK8
SCHEMBL30664236 0.81 MAOA (0.61) MAPKAPK2MAOAMAPK8
SCHEMBL20123053 0.79 CAMKK2 (0.48) LRRK2MAPKAPK2MAOAMAPK8
SCHEMBL30664191 0.79 CAMKK2 (0.48) LRRK2MAPKAPK2MAOAMAPK8
SCHEMBL20122899 0.78 JMJD6 (0.43) CAMK2DSTK4STK3LRRK2JMJD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CAMK2D 1580/4885STK4 2793/4885STK3 2164/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CAMK2D 1580/4885STK4 2793/4885STK3 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.